Wellsheet Granted Patent to Make Electronic Health Records User-Friendly
Intuitive and Predictive Workflow App for EHR:
• Reduces time spent in the EHR, which reduces physician burnout
• Reduces training time and improves productivity
• Increases clinician satisfaction by an order of magnitude
Melior Pharmaceuticals Announces Execution of a License Agreement for Armesocarb by Adhera Therapeutics
Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
Investigational oral beta-lactamase inhibitor VNRX-7145 was well-tolerated with no safety signals up to the highest dose as a single agent
Ceftibuten/VNRX-7145 Combination Phase 1 Study Initiated with Top Line Results Expected Fourth Quarter 2021
Company Plans to Initiate Phase 3 Clinical Trial for Ceftibuten/VNRX-7145 in Second Half 2022
ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory
Clinical and CMC hires to ready initiation of multiple immuno-oncology clinical programs in 2022
Proven business development expertise key to executing global clinical development strategy
R&D hires and lab opening to facilitate critical translational research
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
– All tested doses of REL-1017, including the maximum tolerated dose, showed a highly statistically significant difference in abuse potential vs.
oxycodone with p-values <0.001
– Company to host conference call at 8:30 AM Eastern Time today July 27, 2021
Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study
Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort
Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC
Ride Health and the American Heart Association Partner to Improve Health Equity for Patients Facing Transportation Barriers
American Heart Association’s Social Impact Fund and Bernard J. Tyson Impact Fund invest $500,000 to support comprehensive patient transportation programs at renowned hospitals
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
– IMM-BCP-01 already shown to neutralize all other CDC variants of concern in pre-clinical testing
– IND submission planned for this quarter
CrossBridge Health acquires Geisinger-developed PACER software
CrossBridge to integrate PACER intelligence to improve outcomes for patients with chronic inflammatory diseases